Navigation Links
Translational research patented first experimental treatment against idiopathic pulmonary fibrosis

This release is available in Spanish.

Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage. Patients suffering from it cannot develop with normality pulmonary gas exchange, and have a very reduced quality of life. Because of lack of an effective treatment, they rarely survive 5 years after being diagnosed. Idiopathic pulmonary fibrosis affects 13 out of 100,000 men and 7 out of 100,000 women, normally over 40 years of age. Researchers from the Biomedical Research Institute of Barcelona CSIC (IIBB-CSIC), a centre developing research in the framework of the Institut dInvestigacions Biomdiques August Pi i Sunyer (IDIBAPS), have discovered and patented a method to stop and revert this disease in an animal model. A clinical study will be soon conducted in humans in the Hospital Clnic de Barcelona.

Results of their research work are published in the last issue of the American Journal of Respiratory and Critical Care Medicine (176(12):1261-8). This study has had the collaboration of basic researchers, such as Dr. Anna Serrano-Mollar, and Dr. Oriol Bulbena, first and last signatories of the study; and researchers with a clinical background, such as Dr. Antoni Xaubet, from the Unit of Pneumology of the Hospital Clnic de Barcelona. This turns this work into a paradigm of translational research promoted in IDIBAPS and through other initiatives such as the Network of Centres of Biomedical Research (CIBERs). This research work has been financed through a contribution from the Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III.

Gas exchange is developed in lungs thanks to type 1 pneumocytes in alveoli, cells recovering the inner walls of the alveolar cavity. Occupying the same spaces, there are also type II pneumocytes, precursor cells that repair the damaged alveolar tissue. When idiopathic pulmonary fibrosis appears, this regeneration process cannot be developed correctly and fibrosis advances until respiration is impossible. The technique developed by researchers from the IIBB-CSIC-IDIBAPS consists in a transplantation of type II pneumocytes via intratracheal. In order to monitor correctly the transplanted cells with genetic and fluorescence techniques, sexual chromosomal differences were used. Thus, the disease was induced in female rats, and cells from male rats were transplanted. This is a lowly invasive technique which has permitted to regenerate, for the first time, rat fibrotic alveoli where idiopathic pulmonary fibrosis was induced.

CSIC has patented as a treatment the cell suspension transplanted with this innovative strategy. The world patent will be proved in humans with a clinical study, soon conducted in the Hospital Clnic de Barcelona thanks to the financing of the Fundacin Genoma Espaa and CSIC This study will have the participation of 6 recently diagnosed patients who will receive a suspension of type II pneumocytes coming from a dead donor, since these cells cannot be cultured in the laboratory. All this events throw new and hopeful light into basic and clinical research lines. One of the following steps of researchers will be to try to obtain type II pneumocytes from adult stem cells.


Contact: lex Argem
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer

Related biology news :

1. NIH awards nearly $23M to University of Chicago for translational research
2. AACR, BCRF award inaugural grants in translational breast cancer research
3. Research shows skeleton to be endocrine organ
4. Newly created cancer stem cells could aid breast cancer research
5. Dominant cholesterol-metabolism ideas challenged by new research
6. Researchers identify proteins involved in new neurodegenerative syndrome
7. Texas researchers and educators head for Antarctica
8. MGH researchers describe new way to identify, evolve novel enzymes
9. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
10. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
11. U of MN researchers discover noninvasive diagnostic tool for brain diseases
Post Your Comments:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), ... it will open a state-of-the-art bioinformatics lab, using ,big ... This announcement comes as Liz Scott , co-executive ... Cancer Moonshot Summit in Washington, D.C. ... a participant and advocate of pediatric cancer research and ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
Breaking Biology Technology: